How a wearable-first approach is fixing healthcare’s broken workflows
Saturday, Dec 27, 2025
Reading Time: 8 min
Hospitals are drowning in inefficiency. Nurses spend up to 30% of their time on manual documentation. Patient data gets lost in transcription. And critical vitals? Often recorded too late, or not at all.
Leitwert is changing that. Their platform replaces error-prone manual monitoring with automated, wearable-driven data capture, freeing up clinical staff while improving patient outcomes.
We sat down with Miro Käch, Co-CEO and co-founder of Leitwert, to talk about convincing risk-averse hospitals, navigating regulation without slowing down, and why their device-agnostic approach is a game-changer in a space dominated by proprietary lock-ins. His take?
“Hospitals don’t adopt tech because it’s innovative—they adopt it because it solves three things: workload, economics, and safety. Get those right, and speed follows.”
Here’s how they’re doing it.
OOMNIUM: How do you convince risk-averse hospitals to adopt a tech-driven solution in a sector notorious for slow innovation?
Miro Käch (M.K.): Hospitals are conservative, but cost pressure and staff shortages are forcing change. Our platform removes repetitive tasks like manual vitals, freeing nurses for patient care and enabling more efficient processes, shorter stays, and fewer complications. What convinces executives:
Workload reduction. Nurses immediately feel the difference, improving satisfaction and retention. Clear economics. Time savings and streamlined workflows reduce costs — this is a lever, not a “nice-to-have.” Patient safety. Continuous, automated data cuts missed measurements, delays, and transcription errors, improving early detection.
When urgency is high, adoption is fast. During the 2021 COVID surge, we went from first call to a live prototype on a COVID ward in eight days. Bottom line: we remove workload, improve economics, and enhance safety — once those three boxes are checked, adoption follows.
OOMNIUM: Your device-agnostic approach stands out in a space full of proprietary lock-ins. How do you ensure seamless integration without compromising data integrity or compliance?
M.K.: Being device-agnostic is deliberate. Hospitals need flexibility across use cases without lock-in. We run each device through rigorous validation — intended use, accuracy, robustness, interoperability — in real hospital settings. Our abstraction layer normalizes data so clinicians see clean, standardized outputs regardless of device.
We act as the single solution provider. We handle contracts, support, and training, keeping IT overhead low. For strict data policies, Device+Hub can run fully on-premise. Integration via FHIR, HL7, and IHE eases audits and maintenance. Hospitals get device flexibility with the reliability and compliance of a fully integrated solution—through one point of contact.
OOMNIUM: Regulation can be a growth killer in healthcare. How did you structure your product to move fast without cutting corners on compliance?
M.K.: We built a modular architecture. The core platform—no medical purpose—transforms and stores data securely. Medical applications sit on top, each with its own intended use and classification. This lets us scale efficiently.
We started with non-medical applications for clinical research. Now, we’re launching a patient activity tracking app for orthopaedic surgery—no medical claims initially, with the option to add them later. Speed meets compliance. Expansion stays scalable.
OOMNIUM: You’re raising to hit CHF 1M ARR. Where’s the money going—product, sales, or regulatory? And what’s the top priority for your 2026 targets?
M.K.: Priority one is building reference customers. Funds go toward sales and product refinement to turn users into advocates. We’re expanding channels and partnerships to accelerate adoption.
Regulatory and device integrations run in parallel, but near-term ARR depends most on a strong base of satisfied customers.
OOMNIUM: Your roadmap includes “hospital at home” and care institutions. How do you adapt, and what’s the timeline for commercialisation?
M.K.: The platform already supports home use. It’s live in studies where participants wear devices at home, with data flowing passively. What changes are the applications on top—use-case logic added via our Device+Hub API.
Near term, we focus on hospitals—controlled environments with the biggest impact. Over time, as care shifts home, we’ll target indications with clear clinical need and strong economics, ideally with reimbursement in place. Clinical research applications (e.g., digital endocrinology, chronic care) will translate seamlessly into routine practice at home or in care institutions.
OOMNIUM: DACH alone is a CHF 1B+ TAM. How do you scale beyond direct sales in the region? Partners or in-house teams?
M.K.: Switzerland: direct sales for key hospitals to build references, complemented by select local partners. Germany, Austria, and beyond: primarily partner-led. We work with distributors and established solution providers to scale proven use cases quickly. Direct where we anchor credibility. Partner-first for scale.
OOMNIUM: Exit or standalone? What’s the vision for Leitwert AG, and who’s the ideal strategic partner at this stage?
M.K.: Both paths are viable. The right strategic partner could accelerate impact by expanding reach rapidly. We’ve also built to scale independently with sufficient investment. Ideal partners bring strong hospital access, a large installed base, and a portfolio that Leitwert meaningfully expands—enabling faster adoption through existing relationships.
OOMNIUM: Thank you Miro for your time! Excited to see you succeed with Leitwert!